Y Intercept Hong Kong Ltd Purchases Shares of 36,641 Bruker Corporation (NASDAQ:BRKR)

Y Intercept Hong Kong Ltd bought a new stake in Bruker Corporation (NASDAQ:BRKR - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 36,641 shares of the medical research company's stock, valued at approximately $1,529,000.

Several other hedge funds have also recently made changes to their positions in BRKR. Raymond James Financial Inc. bought a new stake in shares of Bruker in the fourth quarter valued at $661,000. HighTower Advisors LLC grew its position in shares of Bruker by 6.8% in the fourth quarter. HighTower Advisors LLC now owns 6,972 shares of the medical research company's stock valued at $409,000 after purchasing an additional 444 shares in the last quarter. American Century Companies Inc. grew its position in shares of Bruker by 1.2% in the fourth quarter. American Century Companies Inc. now owns 28,971 shares of the medical research company's stock valued at $1,698,000 after purchasing an additional 341 shares in the last quarter. Sei Investments Co. grew its position in shares of Bruker by 21.8% in the fourth quarter. Sei Investments Co. now owns 62,006 shares of the medical research company's stock valued at $3,635,000 after purchasing an additional 11,087 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Bruker in the fourth quarter valued at $1,260,000. 79.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Bruker

In related news, CEO Frank H. Laukien bought 2,608 shares of the stock in a transaction dated Friday, June 6th. The stock was bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the purchase, the chief executive officer owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 27.30% of the company's stock.

Bruker Price Performance

NASDAQ BRKR traded up $1.49 on Friday, reaching $41.94. 3,519,763 shares of the company's stock traded hands, compared to its average volume of 2,322,538. The stock has a market cap of $6.36 billion, a PE ratio of 80.65, a P/E/G ratio of 2.69 and a beta of 1.18. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74. Bruker Corporation has a 12 month low of $34.10 and a 12 month high of $72.94. The stock has a 50-day simple moving average of $39.47 and a 200 day simple moving average of $44.41.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.01. Bruker had a net margin of 2.31% and a return on equity of 19.47%. The business had revenue of $801.40 million during the quarter, compared to the consensus estimate of $763.83 million. During the same period in the previous year, the firm posted $0.53 earnings per share. The firm's revenue for the quarter was up 11.0% on a year-over-year basis. As a group, research analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Monday, June 16th were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend was Monday, June 16th. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BRKR shares. Barclays reduced their price target on Bruker from $50.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Bank of America reduced their price target on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Stifel Nicolaus reduced their target price on Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research report on Thursday, May 8th. Citigroup cut Bruker from a "strong-buy" rating to a "hold" rating and reduced their target price for the stock from $50.00 to $40.00 in a research report on Thursday, May 22nd. Finally, UBS Group reduced their target price on Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $52.89.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.